Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group box 3 pseudogene 22 (HMGB3P22) is a human DNA segment classified as a pseudogene, meaning it resembles the functional high mobility group box 3 (HMGB3) gene but has accumulated mutations that prevent it from encoding a functional protein[2][3]. Pseudogenes like HMGB3P22 are not typically translated into protein and do not function as receptors, enzymes, or other conventional drug targets. While some pseudogenes have been implicated in regulatory roles—such as acting as microRNA sponges, influencing the expression of related genes, or producing regulatory noncoding RNAs—such functions have not been specifically established for HMGB3P22. This pseudogene is annotated in genomic databases for reference but is not a valid therapeutic target and does not interact with known drugs[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group box 3 pseudogene 22 (HMGB3P22).